Establishment Labs projects 25% revenue growth in 2027 as it raises 2026 revenue guidance to more than $274M (NASDAQ:ESTA)

Establishment Labs reported Q3 2026 revenue growth of 33.9%, driven by U.S. market share gains and a 124% increase in minimally invasive revenue. The company achieved positive free cash flow and expects 25% revenue growth in 2027, supported by increased U.S. utilization and FDA approval for Motiva implants in reconstruction. Gross margin expansion of 50 to 100 basis points is projected for 2027, with growth driven by leadership optimization in international markets.

BTIG lowered its price target on Establishment Labs (ESTA) to $93 from $103, maintaining a Buy rating. The company reported Q3 revenue of $72.0M, up 34% YoY, and adjusted EBITDA of $6.4M, exceeding estimates. ESTA raised its 2026 revenue guidance to at least $274M. The stock gained 8.6% over the past week, trading at $69.74. BTIG adjusted its 2027 and 2028 estimates due to a more conservative timeline for U.S. reconstruction approval.

Establishment Labs (ESTA) reported $75.8M in cash, targeting positive free cash flow for 2027. U.S. accounts grew to 2,100, with 30% market share. Minimally invasive revenue rose 124% YoY to $9M, raising full-year guidance to over $40M. International revenue increased 16% YoY, led by Europe. GAAP gross margin was 69.1%, with adjusted margin at 70.8%. The company prepares for potential FDA approval of Motiva implants for reconstruction.

Establishment Labs reported Q3 2026 revenue of $72.0M, up 33.9% YoY, with a net loss of $10.7M. Adjusted EBITDA was $6.4M, and free cash flow was $5.1M, the first positive quarter. The company raised its 2026 revenue outlook to over $274M. U.S. revenue rose 119.0%, and international revenue increased 9.7%.

ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Third Quarter 2026 Financial Results Revenue Increases 33.9% to $72.0 Million, Driven by 119% U.S. Growth Achieves First Quarter of Positive Operating a

Establishment Labs Holdings (ESTA) received FDA clearance for 28 additional implant sizes. The stock has declined 25.80% over 90 days but gained 61.41% over one year. Analysts see a fair value of $92.00, while the stock closed at $65.29. The company faces risks related to market concentration and profitability.